Market Overview

UPDATE: Bank of America Merrill Lynch Reiterates Neutral Rating, Raises PT on CR Bard

Related BCR
Earnings Scheduled For October 22, 2014
The Lutonix® 035 Drug Coated Balloon Is The First And Only FDA-Approved DCB Available In The U.S. For The Treatment Of Femoropopliteal Occlusive Disease

In a report published Monday, Bank of America Merrill Lynch reiterated its Neutral rating on CR Bard (NYSE: BCR), and raised its price target from $103.00 to $113.00.

BofA Merrill Lynch noted, “BCR's model has succeeded in driving a 10%+ revenue CAGR for the last four years, but for the last several quarters, growth has slowed to the 6% range, as the combination of the economy and new competitive dynamics has affected BCR's growth. In BCR's latest three quarters that growth slowed to the 3% range. We have considerable confidence in the BCR management team but given the uncertainty around growth and BCR's premium to the group we see limited upside to the current stock price.”

CR Bard closed on Friday at $102.33.

Latest Ratings for BCR

DateFirmActionFromTo
Dec 2014Wells FargoInitiates Coverage onMarket Perform
Jul 2014CitigroupMaintainsNeutral
Jul 2014JefferiesMaintainsHold

View More Analyst Ratings for BCR
View the Latest Analyst Ratings

Posted-In: Bank of America Merrill LynchAnalyst Color Price Target Analyst Ratings

 

Related Articles (BCR)

Around the Web, We're Loving...

Get Benzinga's Newsletters